

Xiaofang Zuo

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1047930/xiaofang-zuo-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180
papers

4,195
citations

35
h-index

55
g-index

193
ext. papers

5,309
ext. citations

5.9
avg, IF

5.78
L-index

#	Paper	IF	Citations
180	SARS-CoV-2 NSP5 and N protein counteract the RIG-I signaling pathway by suppressing the formation of stress granules.. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7, 22	21	12
179	Design, synthesis, and mechanistic investigations of phenylalanine derivatives containing a benzothiazole moiety as HIV-1 capsid inhibitors with improved metabolic stability. <i>European Journal of Medicinal Chemistry</i> , 2022 , 227, 113903	6.8	1
178	Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.. <i>Journal of Medicinal Chemistry</i> , 2022 ,	8.3	6
177	Novel RNase H inhibitors blocking RNA-directed strand displacement DNA synthesis by HIV-1 reverse transcriptase.. <i>Journal of Molecular Biology</i> , 2022 , 167507	6.5	0
176	Indolylarylsulfones bearing phenylboronic acid and phenylboronate ester functionalities as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 53, 116531	3.4	2
175	Identification of novel potent HIV-1 inhibitors by exploiting the tolerant regions of the NNRTIs binding pocket. <i>European Journal of Medicinal Chemistry</i> , 2021 , 214, 113204	6.8	2
174	2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 4239-4256	8.3	11
173	The development of an effective synthetic route of rilpivirine. <i>BMC Chemistry</i> , 2021 , 15, 22	3.7	4
172	SARS-CoV-2 Entry inhibitors targeting virus-ACE2 or virus-TMPRSS2 interactions. <i>Current Medicinal Chemistry</i> , 2021 ,	4.3	1
171	An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021 , 217, 113380	6.8	6
170	Advances in Natural Products-Based Antiviral Agents 2021 , 21-42		
169	Design, synthesis and anti-HIV evaluation of novel 5-substituted diarylpyrimidine derivatives as potent HIV-1 NNRTIs. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 40, 116195	3.4	2
168	Exploiting the hydrophobic channel of the NNIBP: Discovery of novel diarylpyrimidines as HIV-1 NNRTIs against wild-type and K103N mutant viruses. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 42, 116239†	3.4	1
167	Design, synthesis, and biological evaluation of piperidinyl-substituted [1,2,4]triazolo[1,5-a]pyrimidine derivatives as potential anti-HIV-1 agents with reduced cytotoxicity. <i>Chemical Biology and Drug Design</i> , 2021 , 97, 67-76	2.9	5
166	Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 30, 115927	3.4	6
165	Design, synthesis, and evaluation of "dual-site"-binding diarylpyrimidines targeting both NNIBP and the NNRTI adjacent site of the HIV-1 reverse transcriptase. <i>European Journal of Medicinal Chemistry</i> , 2021 , 211, 113063	6.8	5
164	Discovery of highly potent and selective influenza virus neuraminidase inhibitors targeting 150-cavity. <i>European Journal of Medicinal Chemistry</i> , 2021 , 212, 113097	6.8	3

163	Exploiting the tolerant region I of the non-nucleoside reverse transcriptase inhibitor (NNRTI) binding pocket. Part 2: Discovery of diarylpyrimidine derivatives as potent HIV-1 NNRTIs with high Fsp values and favorable drug-like properties. <i>European Journal of Medicinal Chemistry</i> , 2021 , 213, 113051	6.8	4
162	Punicalagin is a neuraminidase inhibitor of influenza viruses. <i>Journal of Medical Virology</i> , 2021 , 93, 3465-3472	3.7	7
161	Search, Identification, and Design of Effective Antiviral Drugs Against Pandemic Human Coronaviruses. <i>Advances in Experimental Medicine and Biology</i> , 2021 , 1322, 219-260	3.6	1
160	Recent developments in the medicinal chemistry of single boron atom-containing compounds. <i>Acta Pharmaceutica Sinica B</i> , 2021 , 11, 3035-3059	15.5	28
159	Boronic acid-containing diarylpyrimidine derivatives as novel HIV-1 NNRTIs: Design, synthesis and biological evaluation. <i>Chinese Chemical Letters</i> , 2021 ,	8.1	4
158	Discovery of Novel Dihydrothiopyrano[4,3-]pyrimidine Derivatives as Potent HIV-1 NNRTIs with Significantly Reduced hERG Inhibitory Activity and Improved Resistance Profiles. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 13658-13675	8.3	2
157	Medicinal chemistry strategies towards the development of effective SARS-CoV-2 inhibitors. <i>Acta Pharmaceutica Sinica B</i> , 2021 ,	15.5	5
156	Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies. <i>Journal of Medicinal Chemistry</i> , 2021 , 64, 13604-13621	8.3	1
155	Discovery of potent and selective Cdc25 phosphatase inhibitors via rapid assembly and in situ screening of Quinonoid-focused libraries. <i>Bioorganic Chemistry</i> , 2021 , 115, 105254	5.1	2
154	Design, synthesis, and antiviral activity of phenylalanine derivatives as HIV-1 capsid inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2021 , 48, 116414	3.4	0
153	Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP. <i>Bioorganic Chemistry</i> , 2021 , 116, 105353	5.1	1
152	Discovery, optimization, and target identification of novel coumarin derivatives as HIV-1 reverse transcriptase-associated ribonuclease H inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021 , 225, 113769	6.8	3
151	Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021 , 225, 113780	6.8	2
150	Design, synthesis, and mechanism study of dimerized phenylalanine derivatives as novel HIV-1 capsid inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2021 , 226, 113848	6.8	4
149	Discovery of potential dual-target prodrugs of HIV-1 reverse transcriptase and nucleocapsid protein 7. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020 , 30, 127287	2.9	
148	Recent Developments in Small Molecular HIV-1 and Hepatitis B Virus RNase H Inhibitors 2020 , 273-292		
147	Inhibitors of SARS-CoV-2 Entry: Current and Future Opportunities. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 12256-12274	8.3	111
146	Targeting the entry step of SARS-CoV-2: a promising therapeutic approach. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 98	21	13

145	New techniques and strategies in drug discovery. <i>Chinese Chemical Letters</i> , 2020 , 31, 1695-1708	8.1	45
144	In situ click chemistry-based rapid discovery of novel HIV-1 NNRTIs by exploiting the hydrophobic channel and tolerant regions of NNIBP. <i>European Journal of Medicinal Chemistry</i> , 2020 , 193, 112237	6.8	11
143	Design, diversity-oriented synthesis and biological evaluation of novel heterocycle derivatives as non-nucleoside HBV capsid protein inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020 , 202, 112495	6.8	6
142	Structure-Activity Relationship Exploration of NNIBP Tolerant Region I Leads to Potent HIV-1 NNRTIs. <i>ACS Infectious Diseases</i> , 2020 , 6, 2225-2234	5.5	8
141	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020 , 191, 112147	6.8	5
140	Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities. <i>European Journal of Medicinal Chemistry</i> , 2020 , 190, 112085	6.8	37
139	Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 1298-1312	8.3	20
138	Medicinal chemistry insights into novel CDC25 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2020 , 201, 112374	6.8	11
137	Structure-Based Bioisosterism Yields HIV-1 NNRTIs with Improved Drug-Resistance Profiles and Favorable Pharmacokinetic Properties. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 4837-4848	8.3	20
136	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I/MDA-5 signaling. <i>Signal Transduction and Targeted Therapy</i> , 2020 , 5, 299	21	123
135	Discovery of novel 1,2,3-triazole oseltamivir derivatives as potent influenza neuraminidase inhibitors targeting the 430-cavity. <i>European Journal of Medicinal Chemistry</i> , 2020 , 187, 111940	6.8	12
134	Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility. <i>European Journal of Medicinal Chemistry</i> , 2020 , 206, 112811	6.8	3
133	Discovery and optimizing polycyclic pyridone compounds as anti-HBV agents. <i>Expert Opinion on Therapeutic Patents</i> , 2020 , 30, 715-721	6.8	1
132	Fsp: A new parameter for drug-likeness. <i>Drug Discovery Today</i> , 2020 , 25, 1839-1845	8.8	52
131	Discovery and optimization of benzenesulfonamides-based hepatitis B virus capsid modulators via contemporary medicinal chemistry strategies. <i>European Journal of Medicinal Chemistry</i> , 2020 , 206, 112714	6.8	8
130	Novel Human Urate Transporter 1 Inhibitors as Hypouricemic Drug Candidates with Favorable Druggability. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 10829-10854	8.3	8
129	Design, synthesis, and evaluation of novel heteroaryldihydropyrimidine derivatives as non-nucleoside hepatitis B virus inhibitors by exploring the solvent-exposed region. <i>Chemical Biology and Drug Design</i> , 2020 , 95, 567-583	2.9	8
128	Exploring the hydrophobic channel of NNIBP leads to the discovery of novel piperidine-substituted thiophene[3,2-]pyrimidine derivatives as potent HIV-1 NNRTIs. <i>Acta Pharmaceutica Sinica B</i> , 2020 , 10, 878-894	15.5	26

127	Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities. <i>Journal of Medicinal Chemistry</i> , 2020 , 63, 4790-4810	8.3	18
126	Identification of Chebulinic Acid and Chebulagic Acid as Novel Influenza Viral Neuraminidase Inhibitors. <i>Frontiers in Microbiology</i> , 2020 , 11, 182	5.7	17
125	Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial libraries. <i>European Journal of Medicinal Chemistry</i> , 2019 , 183, 111696	6.8	11
124	Exploiting the Tolerant Region I of the Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Binding Pocket: Discovery of Potent Diarylpyrimidine-Typed HIV-1 NNRTIs against Wild-Type and E138K Mutant Virus with Significantly Improved Water Solubility and Favorable Safety Profiles. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 2083-2098	8.3	47
123	Recent applications of click chemistry in drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2019 , 14, 779-789	7.8	70
122	Design, synthesis and biological evaluation of "Multi-Site"-binding influenza virus neuraminidase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2019 , 178, 64-80	6.8	18
121	Contemporary medicinal-chemistry strategies for discovery of blood coagulation factor Xa inhibitors. <i>Expert Opinion on Drug Discovery</i> , 2019 , 14, 915-931	6.2	6
120	Molecular design opportunities presented by solvent-exposed regions of target proteins. <i>Medicinal Research Reviews</i> , 2019 , 39, 2194-2238	14.4	16
119	Overview of Recent Strategic Advances in Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 9375-9414	8.3	53
118	Resurrecting the Condemned: Identification of N-Benzoxaborole Benzofuran GSK8175 as a Clinical Candidate with Reduced Metabolic Liability. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 3251-3253	8.3	7
117	Designing influenza polymerase acidic endonuclease inhibitors via a privileged scaffold re-evolution/refining strategy. <i>Future Medicinal Chemistry</i> , 2019 ,	4.1	8
116	Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 236	5.3	8
115	Discovery of novel anti-influenza agents via contemporary medicinal chemistry strategies (2014-2018 update). <i>Future Medicinal Chemistry</i> , 2019 , 11, 375-378	4.1	5
114	Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing. <i>European Journal of Medicinal Chemistry</i> , 2019 , 182, 111619	6.8	7
113	Design, synthesis and biological evaluation of 3-hydroxyquinazoline-2,4(1H,3H)-diones as dual inhibitors of HIV-1 reverse transcriptase-associated RNase H and integrase. <i>Bioorganic and Medicinal Chemistry</i> , 2019 , 27, 3836-3845	3.4	7
112	Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors. <i>Communications Chemistry</i> , 2019 , 2,	6.3	15
111	Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019). <i>Expert Opinion on Therapeutic Patents</i> , 2019 , 29, 871-879	6.8	20
110	Discovery of novel 1,4-disubstituted 1,2,3-triazole phenylalanine derivatives as HIV-1 capsid inhibitors. <i>RSC Advances</i> , 2019 , 9, 28961-28986	3.7	24

109	Design, synthesis, and biologic evaluation of novel galloyl derivatives as HIV-1 RNase H inhibitors. <i>Chemical Biology and Drug Design</i> , 2019 , 93, 582-589	2.9	8
108	Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs. <i>Bioorganic and Medicinal Chemistry</i> , 2019 , 27, 447-456	3.4	12
107	Contemporary medicinal-chemistry strategies for the discovery of selective butyrylcholinesterase inhibitors. <i>Drug Discovery Today</i> , 2019 , 24, 629-635	8.8	24
106	Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 1484-1501	8.3	41
105	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors by exploring the structure-activity relationship of solvent-exposed regions I. <i>Chemical Biology and Drug Design</i> , 2019 , 93, 430-437	2.9	8
104	Efficient drug discovery by rational lead hybridization based on crystallographic overlay. <i>Drug Discovery Today</i> , 2019 , 24, 805-813	8.8	15
103	The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic. <i>Journal of Medicinal Chemistry</i> , 2019 , 62, 4851-4883	8.3	74
102	First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018 , 28, 1348-1351	2.9	8
101	Discovery of Novel Diarylpyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the "NNRTI Adjacent" Binding Site. <i>ACS Medicinal Chemistry Letters</i> , 2018 , 9, 334-338	4.3	25
100	Further Exploring Solvent-Exposed Tolerant Regions of Allosteric Binding Pocket for Novel HIV-1 NNRTIs Discovery. <i>ACS Medicinal Chemistry Letters</i> , 2018 , 9, 370-375	4.3	21
99	The discovery of novel diarylpyri(mi)dine derivatives with high level activity against a wide variety of HIV-1 strains as well as against HIV-2. <i>Bioorganic and Medicinal Chemistry</i> , 2018 , 26, 2051-2060	3.4	7
98	Discovery of C-1 modified oseltamivir derivatives as potent influenza neuraminidase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2018 , 146, 220-231	6.8	21
97	Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives. <i>European Journal of Medicinal Chemistry</i> , 2018 , 147, 150-162	6.8	35
96	Current insights into anti-HIV drug discovery and development: a review of recent patent literature (2014-2017). <i>Expert Opinion on Therapeutic Patents</i> , 2018 , 28, 299-316	6.8	27
95	Influenza A virus polymerase: an attractive target for next-generation anti-influenza therapeutics. <i>Drug Discovery Today</i> , 2018 , 23, 503-518	8.8	24
94	Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus. <i>European Journal of Medicinal Chemistry</i> , 2018 , 151, 339-350	6.8	44
93	Design, synthesis, and antiviral evaluation of novel hydrazone-substituted thiophene[3,2-d]pyrimidine derivatives as potent human immunodeficiency virus-1 inhibitors. <i>Chemical Biology and Drug Design</i> , 2018 , 92, 2009-2021	2.9	8
92	5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase. <i>European Journal of Medicinal Chemistry</i> , 2018 , 155, 714-724	6.8	21

91	Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013-2016): Opportunities and Challenges. <i>Current Medicinal Chemistry</i> , 2018 , 25, 1682-1702	4.3	30
90	Design, synthesis and biological evaluation of tacrine-1,2,3-triazole derivatives as potent cholinesterase inhibitors. <i>MedChemComm</i> , 2018 , 9, 149-159	5	39
89	Development of a practical synthesis of etravirine via a microwave-promoted amination. <i>Chemistry Central Journal</i> , 2018 , 12, 144		1
88	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 9976-9999	8.3	24
87	Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-]pyrimidine non-nucleoside inhibitors. <i>ELife</i> , 2018 , 7,	8.9	41
86	Discovery of phenylalanine derivatives as potent HIV-1 capsid inhibitors from click chemistry-based compound library. <i>European Journal of Medicinal Chemistry</i> , 2018 , 158, 478-492	6.8	36
85	Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 6379-6397	8.3	32
84	Inhibitors of Influenza Virus Polymerase Acidic (PA) Endonuclease: Contemporary Developments and Perspectives. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 3533-3551	8.3	40
83	Discovery of uracil-bearing DAPYs derivatives as novel HIV-1 NNRTIs via crystallographic overlay-based molecular hybridization. <i>European Journal of Medicinal Chemistry</i> , 2017 , 130, 209-222	6.8	17
82	Novel fused pyrimidine and isoquinoline derivatives as potent HIV-1 NNRTIs: a patent evaluation of WO2016105532A1, WO2016105534A1 and WO2016105564A1. <i>Expert Opinion on Therapeutic Patents</i> , 2017 , 27, 383-391	6.8	16
81	Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants. <i>Journal of Medicinal Chemistry</i> , 2017 , 60, 4424-4443	8.3	65
80	Design, synthesis and primary biological evaluation of the novel 2-pyridone derivatives as potent non-nucleoside HBV inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2017 , 136, 144-153	6.8	28
79	Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays. <i>Bioorganic and Medicinal Chemistry</i> , 2017 , 25, 4397-4406	3.4	16
78	Discovery of Thiophene[3,2-]pyrimidine Derivatives as Potent HIV-1 NNRTIs Targeting the Tolerant Region I of NNIBP. <i>ACS Medicinal Chemistry Letters</i> , 2017 , 8, 1188-1193	4.3	21
77	1-Hydroxypyrido[2,3-d]pyrimidin-2(1H)-ones as novel selective HIV integrase inhibitors obtained via privileged substructure-based compound libraries. <i>Bioorganic and Medicinal Chemistry</i> , 2017 , 25, 5779-5789	3.4	12
76	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs. <i>European Journal of Medicinal Chemistry</i> , 2017 , 140, 383-391	6.8	11
75	Identification of spirocyclic or phosphate substituted quinolizine derivatives as novel HIV-1 integrase inhibitors: a patent evaluation of WO2016094197A1, WO2016094198A1 and WO2016154527A1. <i>Expert Opinion on Therapeutic Patents</i> , 2017 , 27, 1277-1286	6.8	5
74	One-minute self-assembly of millimetre-long DAST crystalline microbelts via substrate-supported rapid evaporation crystallization. <i>RSC Advances</i> , 2017 , 7, 31691-31695	3.7	7

73	Novel diaryltriazines with a picolinonitrile moiety as potent HIV-1 RT inhibitors: a patent evaluation of WO2016059647(A2). <i>Expert Opinion on Therapeutic Patents</i> , 2017 , 27, 9-15	6.8	5
72	Discovery of novel piperidine-substituted indolylarylsulfones as potent HIV NNRTIs via structure-guided scaffold morphing and fragment rearrangement. <i>European Journal of Medicinal Chemistry</i> , 2017 , 126, 190-201	6.8	15
71	The development of an effective synthetic route of lesinurad (RDEA594). <i>Chemistry Central Journal</i> , 2017 , 11, 86		8
70	Discovery of bioactive molecules from CuAAC click-chemistry-based combinatorial libraries. <i>Drug Discovery Today</i> , 2016 , 21, 118-132	8.8	101
69	Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 7991-8007	8.3	84
68	Design, synthesis and evaluation of pyrazole derivatives as non-nucleoside hepatitis B virus inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2016 , 123, 202-210	6.8	24
67	Arylazolyl(aziny)lthioacetanilides: Part 19: Discovery of Novel Substituted Imidazo[4,5-b]pyridin-2-ylthioacetanilides as Potent HIV NNRTIs Via a Structure-based Bioisosterism Approach. <i>Chemical Biology and Drug Design</i> , 2016 , 88, 241-53	2.9	7
66	Discovery of novel anti-HIV agents via Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) click chemistry-based approach. <i>Expert Opinion on Drug Discovery</i> , 2016 , 11, 857-71	6.2	26
65	Pyrazolo[1,5-a]pyrimidine-based macrocycles as novel HIV-1 inhibitors: a patent evaluation of WO2015123182. <i>Expert Opinion on Therapeutic Patents</i> , 2016 , 26, 979-86	6.8	6
64	Design, synthesis and evaluation of novel HIV-1 NNRTIs with dual structural conformations targeting the entrance channel of the NNRTI binding pocket. <i>European Journal of Medicinal Chemistry</i> , 2016 , 115, 53-62	6.8	16
63	Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1. <i>Expert Opinion on Therapeutic Patents</i> , 2016 , 26, 281-9	6.8	19
62	Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket. <i>European Journal of Medicinal Chemistry</i> , 2016 , 109, 294-304	6.8	26
61	Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities. <i>European Journal of Medicinal Chemistry</i> , 2016 , 114, 65-78	6.8	26
60	Substituted indoles as HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent evaluation (WO2015044928). <i>Expert Opinion on Therapeutic Patents</i> , 2016 , 26, 629-35	6.8	2
59	Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. <i>Journal of Medicinal Chemistry</i> , 2016 , 59, 2849-78	8.3	199
58	Design, Synthesis, and Biological Evaluation of Novel 2-(Pyridin-3-yloxy)acetamide Derivatives as Potential Anti-HIV-1 Agents. <i>Chemical Biology and Drug Design</i> , 2016 , 87, 283-9	2.9	6
57	Design, synthesis, and biological evaluation of novel 5-Alkyl-6-Adamantylmethylpyrimidin-4(3H)-ones as HIV-1 non-nucleoside reverse-transcriptase inhibitors. <i>Chemical Biology and Drug Design</i> , 2016 , 88, 380-5	2.9	2
56	Structural optimization of pyridine-type DAPY derivatives to exploit the tolerant regions of the NNRTI binding pocket. <i>European Journal of Medicinal Chemistry</i> , 2016 , 121, 352-363	6.8	20

55	First discovery of novel 3-hydroxy-quinazoline-2,4(1H,3H)-diones as specific anti-vaccinia and adenovirus agents via a privileged scaffoldRefining approach. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2016 , 26, 5182-5186	2.9	25
54	Arylazolyl(azinyl)thioacetanilides. Part 20: Discovery of novel purinylthioacetanilides derivatives as potent HIV-1 NNRTIs via a structure-based bioisosterism approach. <i>Bioorganic and Medicinal Chemistry</i> , 2016 , 24, 4424-4433	3.4	7
53	Discovery of potent HIV-1 non-nucleoside reverse transcriptase inhibitors from arylthioacetanilide structural motif. <i>European Journal of Medicinal Chemistry</i> , 2015 , 102, 167-79	6.8	21
52	Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators. <i>Journal of Medicinal Chemistry</i> , 2015 , 58, 7611-33	8.3	34
51	Discovery of HCV NS5B thumb site I inhibitors: core-refining from benzimidazole to indole scaffold. <i>European Journal of Medicinal Chemistry</i> , 2015 , 94, 218-28	6.8	19
50	Fragment-based approaches to anti-HIV drug discovery: state of the art and future opportunities. <i>Expert Opinion on Drug Discovery</i> , 2015 , 10, 1271-81	6.2	6
49	Non-nucleoside anti-HBV agents: advances in structural optimization and mechanism of action investigations. <i>MedChemComm</i> , 2015 , 6, 521-535	5	13
48	Design, Synthesis, and Anti-HIV Evaluation of Novel Triazine Derivatives Targeting the Entrance Channel of the NNRTI Binding Pocket. <i>Chemical Biology and Drug Design</i> , 2015 , 86, 122-8	2.9	13
47	8-Hydroxyquinoline: a privileged structure with a broad-ranging pharmacological potential. <i>MedChemComm</i> , 2015 , 6, 61-74	5	132
46	3D-QSAR and docking studies on piperidine-substituted diarylpyrimidine analogues as HIV-1 reverse transcriptase inhibitors. <i>Medicinal Chemistry Research</i> , 2015 , 24, 3314-3326	2.2	7
45	Medicinal chemistry insights in the discovery of novel LSD1 inhibitors. <i>Epigenomics</i> , 2015 , 7, 1379-96	4.4	32
44	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. <i>European Journal of Medicinal Chemistry</i> , 2015 , 93, 330-7	6.8	37
43	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 3: optimization of [1,2,4]triazolo[1,5-a]pyrimidine core via structure-based and physicochemical property-driven approaches. <i>European Journal of Medicinal Chemistry</i> , 2015 , 92, 754-65	6.8	69
42	Synthesis and Biological Evaluation of a Series of 2-((1-substituted-1H-1,2,3-triazol-4-yl)methylthio)-6-(naphthalen-1-ylmethyl)pyrimidin-4(3H)-one As Potential HIV-1 Inhibitors. <i>Chemical Biology and Drug Design</i> , 2015 , 86, 614-8	2.9	13
41	Synthesis and Preliminary Antiviral Activities of Piperidine-substituted Purines against HIV and Influenza A/H1N1 Infections. <i>Chemical Biology and Drug Design</i> , 2015 , 86, 568-77	2.9	14
40	Design, Synthesis, and Biological Evaluation of Novel 4-Aminopiperidinyl-linked 3,5-Disubstituted-1,2,6-thiadiazine-1,1-dione Derivatives as HIV-1 NNRTIs. <i>Chemical Biology and Drug Design</i> , 2015 , 86, 107-13	2.9	3
39	Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 2052-9	3.4	55
38	Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 1863-72	3.4	35

37	Design, synthesis and preliminary SAR studies of novel N-arylmethyl substituted piperidine-linked aniline derivatives as potent HIV-1 NNRTIs. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 633-42	3.4	20
36	Recent advances in the structure-based rational design of TNKSI. <i>Molecular BioSystems</i> , 2014 , 10, 2783-99		18
35	Design, synthesis and biological evaluation of novel trimethylpyrazine-2-carboxyloxy-cinnamic acids as potent cardiovascular agents. <i>MedChemComm</i> , 2014 , 5, 711	5	6
34	Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach. <i>European Journal of Medicinal Chemistry</i> , 2014 , 85, 293-303	6.8	44
33	Discovery of small molecular inhibitors targeting HIV-1 gp120-CD4 interaction driven from BMS-378806. <i>European Journal of Medicinal Chemistry</i> , 2014 , 86, 481-90	6.8	20
32	Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2014 , 22, 5290-7	3.4	9
31	Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization. <i>European Journal of Medicinal Chemistry</i> , 2014 , 87, 52-62	6.8	31
30	Discovery of novel diarylpyrimidines as potent HIV NNRTIs via a structure-guided core-refining approach. <i>European Journal of Medicinal Chemistry</i> , 2014 , 80, 112-21	6.8	24
29	Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate. <i>European Journal of Medicinal Chemistry</i> , 2014 , 82, 293-307	6.8	29
28	Discovery of nitropyridine derivatives as potent HIV-1 non-nucleoside reverse transcriptase inhibitors via a structure-based core refining approach. <i>European Journal of Medicinal Chemistry</i> , 2014 , 76, 531-8	6.8	15
27	HIV-1 NNRTIs: structural diversity, pharmacophore similarity, and implications for drug design. <i>Medicinal Research Reviews</i> , 2013 , 33 Suppl 1, E1-72	14.4	147
26	Discovery of novel pyridazinylthioacetamides as potent HIV-1 NNRTIs using a structure-based bioisosterism approach. <i>MedChemComm</i> , 2013 , 4, 810	5	7
25	Design, synthesis and biological evaluation of novel ligustrazinylated derivatives as potent cardiovascular agents. <i>MedChemComm</i> , 2013 , 4, 827-832	5	6
24	Facile Synthesis of Derivatives of 1,1,3-Trioxo-2H,4H-pyrrolo[1,2-b][1,2,4,6]thiatiazine: A New Heterocyclic System. <i>Heteroatom Chemistry</i> , 2013 , 24, 495-501	1.2	3
23	Multivalent Agents: A Novel Concept and Preliminary Practice in Anti-HIV Drug Discovery. <i>Current Medicinal Chemistry</i> , 2013 , 20, 815-832	4.3	20
22	Multivalent agents: a novel concept and preliminary practice in Anti-HIV drug discovery. <i>Current Medicinal Chemistry</i> , 2013 , 20, 815-32	4.3	17
21	Discovery of novel 2-(3-(2-chlorophenyl)pyrazin-2-ylthio)-N-arylacetamides as potent HIV-1 inhibitors using a structure-based bioisosterism approach. <i>Bioorganic and Medicinal Chemistry</i> , 2012 , 20, 6795-802	3.4	13
20	Structure-based bioisosterism design, synthesis and biological evaluation of novel 1,2,4-triazin-6-ylthioacetamides as potent HIV-1 NNRTIs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012 , 22, 7155-62	2.9	33

19	Arylazolyl(aziny)lthioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. <i>Archives of Pharmacal Research</i> , 2012 , 35, 975-86	6.1	11
18	Novel HIV-1 non-nucleoside reverse transcriptase inhibitors: a patent review (2005 - 2010). <i>Expert Opinion on Therapeutic Patents</i> , 2011 , 21, 717-96	6.8	44
17	Arylazolylthioacetanilide. Part 8: Design, synthesis and biological evaluation of novel 2-(2-(2,4-dichlorophenyl)-2H-1,2,4-triazol-3-ylthio)-N-arylamides as potent HIV-1 inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2011 , 46, 5039-45	6.8	24
16	Functional roles of azoles motif in anti-HIV agents. <i>Current Medicinal Chemistry</i> , 2011 , 18, 29-46	4.3	24
15	Cosalane and its analogues: a unique class of anti-HIV agents. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010 , 10, 966-76	3.2	8
14	Blocking nuclear import of pre-integration complex: an emerging anti-HIV-1 drug discovery paradigm. <i>Current Medicinal Chemistry</i> , 2010 , 17, 495-503	4.3	13
13	Naturally occurring and synthetic bioactive molecules as novel non-nucleoside HBV inhibitors. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010 , 10, 162-71	3.2	19
12	Synthesis and anti-HIV activity evaluation of novel N ² -arylidene-2-[1-(naphthalen-1-yl)-1H-tetrazol-5-ylthio]acetohydrazides. <i>Medicinal Chemistry Research</i> , 2010 , 19, 652-663	2.2	21
11	1,2,3-thiadiazole thioacetanilides. Part 2: Synthesis and biological evaluation of a new series of 2-[[4-(3,4-dichlorophenyl)-1,2,3-thiadiazol-5-yl]sulfonyl]acetanilides as HIV-1 inhibitors. <i>Chemistry and Biodiversity</i> , 2010 , 7, 1717-27	2.5	20
10	Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update. <i>Current Medicinal Chemistry</i> , 2009 , 16, 2876-89	4.3	47
9	Sulfanyltriazole/tetrazoles: a promising class of HIV-1 NNRTIs. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009 , 9, 1014-23	3.2	39
8	Design strategies of novel NNRTIs to overcome drug resistance. <i>Current Medicinal Chemistry</i> , 2009 , 16, 3903-17	4.3	83
7	Designed multiple ligands: an emerging anti-HIV drug discovery paradigm. <i>Current Pharmaceutical Design</i> , 2009 , 15, 1893-917	3.3	57
6	Novel 1,2,3-thiadiazole derivatives as HIV-1 NNRTIs with improved potency: Synthesis and preliminary SAR studies. <i>Bioorganic and Medicinal Chemistry</i> , 2009 , 17, 5920-7	3.4	71
5	1,2,3-Selenadiazole thioacetanilides: synthesis and anti-HIV activity evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2009 , 17, 6374-9	3.4	48
4	Synthesis and anti-HIV activity evaluation of 2-(4-(naphthalen-2-yl)-1,2,3-thiadiazol-5-ylthio)-N-acetamides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2009 , 44, 4648-53	6.8	43
3	Synthesis and biological evaluation of imidazole thioacetanilides as novel non-nucleoside HIV-1 reverse transcriptase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2009 , 17, 5775-81	3.4	48
2	Recent advances in antiviral activity of benzo/heterothiadiazine dioxide derivatives. <i>Current Medicinal Chemistry</i> , 2008 , 15, 1529-40	4.3	25

1 1,2,3-Thiadiazole thioacetanilides as a novel class of potent HIV-1 non-nucleoside reverse transcriptase inhibitors. *Bioorganic and Medicinal Chemistry Letters*, **2008**, 18, 5368-71

2.9 60